Staged Biliary Reconstruction After Orthotopic Liver Transplantation: A Practical Surgical Strategy for High-Acuity Adult Recipients

Terra Pearson, MD,1 Michael A. Zimmerman, MD,1 Joohyun Kim, MD, PhD,1 Patrick A. Palines,2 Calvin M. Eriksen, MD,1 Melissa Wong, MD,1 Motaz A. Selim, MD,1 Daniela Markovic, MS,3 and Johnny C. Hong, MD1

INTRODUCTION

Biliary complications (BC) following orthotopic liver transplantation (OLT) is strongly associated with inferior patient outcomes and increased healthcare cost. BC in high-acuity patients can be lethal. While the utility of staged biliary reconstruction after liver transplantation (SBRALT) has been reported in adult and pediatric OLT, biliary outcome data are scarce. We sought to evaluate the clinical utility and outcomes of SBRALT in high-acuity transplant recipients.

Background. Biliary complications (BC) following orthotopic liver transplantation (OLT) is strongly associated with inferior patient outcomes and increased healthcare cost. BC in high-acuity patients can be lethal. While the utility of staged biliary reconstruction after liver transplantation (SBRALT) has been reported in adult and pediatric OLT, biliary outcome data are scarce. We sought to evaluate the clinical utility and outcomes of SBRALT in high-acuity transplant recipients.

METHODS

We conducted an analysis from our prospective database of 149 adult OLT between January 1, 2012, and September 30, 2017. Mean follow-up was 26 months. Variables were compared for Group I: one-stage OLT with biliary reconstruction (N = 58) versus Group II: SBRALT (N = 91).

RESULTS.

Compared with Group I, patients in Group II had higher acuity of illness: median model for end-stage liver disease scores (19 vs 35, P = 0.002), requirement for pretransplant intensive care unit (29.3% vs 54.9%, P = 0.022), pretransplant renal replacement therapy (15.5% vs 48.4%), estimated blood loss (2000 vs 4750 mL, P < 0.001), and intraoperative packed red blood cells transfusion (4 vs 10 units, P < 0.001). For Group II, biliary reconstruction was performed between 1 and 6 days after OLT. Hepaticojejunostomy was performed in 8.6% (Group I) and 26.4% (Group II), P = 0.010. For Groups I and II, BC rates (8.6% vs 7.7%, P = 0.955) and 1-year graft failure-free survival rates (89.7% vs 88.2%, P = 0.845) were comparable.

CONCLUSIONS.

Graft failure-free survival and biliary outcomes of SBRALT in high-acuity recipients are excellent and comparable to one-stage OLT for low-risk patients. SBRALT is a practical surgical strategy in complex OLT.

Received 3 June 2019. Revision received 23 June 2019. Accepted 24 June 2019.

1 Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI.
2 Medical College of Wisconsin Medical School, Milwaukee, WI.
3 Division of General Internal Medicine and Health Services Research, Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, CA.

T.P., M.A.Z., J.K., P.A.P., C.M.E., M.W., M.A.S., D.M., and J.C.H. participated in research design, participated in the performance of research, and contributed new reagents or analytic tools. T.P., M.A.Z., J.K., D.M., and J.C.H. participated in the writing of the paper. T.P., M.A.Z., D.M., and J.C.H. participated in data analysis.

The authors declare no conflicts of interest.

This work was supported in part by The Kevin T. Cottrell Memorial Fund for Organ Transplantation Research.

Correspondence: Johnny C. Hong, MD, Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Transplant Center, 9220 W. Wisconsin Avenue, CFC 2nd Floor, Suite H2200, Milwaukee, WI 53226, (hong@mcw.edu).

Copyright © 2019 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ISSN: 2373-8731
DOI: 10.1097/TXD.0000000000000924
the intensive care unit after liver graft revascularization prior to a second procedure of biliary reconstruction, staged biliary reconstruction after liver transplantation (SBRALT).6,7 In high-acuity patients undergoing OLT, SBRALT offers the benefit of performing the biliary reconstruction under a more favorable hemodynamic state and operative milieu. While the utility of a 2-stage OLT with delayed biliary reconstruction has been reported in adult and pediatric OLT, biliary outcome data are scarce.6,7 We sought to analyze the clinical utility and outcomes of SBRALT in high-acuity adult transplant recipients.

MATERIALS AND METHODS

Data Collection

Using a prospectively collected transplantation database, we conducted a retrospective review of all patients ≥18 years of age who underwent OLT at the Froedtert & The Medical College of Wisconsin Transplantation Center from January 1, 2012, to September 30, 2017. The median posttransplant follow-up duration was 26 months. The Medical College of Wisconsin Institutional Review Board approved the study.

Patient, Donor, and Operative Variables

All patients with end-stage liver disease were evaluated for OLT by a multidisciplinary team. The current MELD system was utilized for patient waitlist prioritization and organ allocation.5 Variables collected for analysis included for both patients and donors: age, ethnicity, gender, history of diabetes mellitus, and body mass index; for recipients, indication for OLT, number of prior OLT, MELD score or United Network for Organ Sharing status 1 category at time of OLT, presence of severe portal hypertension (defined as refractory ascites and variceal hemorrhage requiring placement of transjugular intrahepatic portosystemic shunt),6,10 the need for pretransplant hospitalization, pretransplant intensive care unit (ICU) management including ventilator and vasopressor support, and pre and intraoperative continuous renal replacement therapy (CRRT); and for donors, length of hospitalization before donation, cause of death, need for vasopressors prior to donation, and deceased donor liver graft type (whole organ vs partial/split graft).

Operative variables included in the analysis were type and timing of biliary reconstruction (one stage vs SBRALT), graft cold and warm ischemia times, the intraoperative body temperature and acid-base status of the patient, presence of intraabdominal adhesions, visceral edema or bowel distention, the need for venovenous bypass, and requirement for blood transfusion, as well as the incidence of postperfusion syndrome. Posttransplant variables analyzed were post-OLT ICU and hospital length of stay, the need for CRRT, serum blood chemistry, and laboratory tests.

Timing and Technique of Biliary Reconstruction

The surgical procedure for OLT was performed in the standard manner, with replacement of the recipient inferior vena cava in most cases.11 A one-stage OLT with biliary anastomosis at the same time of transplantation was initially intended for all patients. SBRALT was instituted for patients who exhibited the following after hepatic graft reperfusion prior to biliary reconstruction: hemodynamic instability requiring high doses of vasopressor agents, severe coagulopathy requiring massive transfusion of blood products, metabolic acidosis, hypothermia, the additional need for an extensive lysis of intraabdominal adhesions, and significant visceral edema and bowel distention.

Prior to abdominal wall closure, a hepatic graft cholecystectomy was performed and a biliary catheter was inserted into the hepatic graft bile duct and secured with 6–0 polypropylene (Prolene) suture. The biliary catheter was externalized and secured to the skin. The cut-end of the native (recipient) bile duct was ligated with a 2–0 silk suture.7

The second stage of biliary reconstruction, either choledochocholedochostomy (duct-to-duct) or hepaticojejunostomy, was performed between 1 and 6 days after OLT once the patient has achieved hemodynamic stability, improvement of hepatic graft function, and reduction or resolution of visceral edema or bowel distention. The choledochocholedochostomy was accomplished with interrupted stitches using monofilament absorbable sutures. In cases of size mismatch between the native and donor bile ducts, ductoplasty was performed. For the biliary anastomosis, the posterior bile duct wall stitches were placed prior to those for the anterior wall and all the sutured knots were tied extraluminally. T-tube was utilized selectively. For patients with T-tube, a T-tube cholangiography was performed 5 days after biliary reconstruction and capped if cholangiogram demonstrated normal findings and the serum total bilirubin level had decreased to <5 mg/dL. At 3 months after OLT, a follow-up T-tube cholangiography was performed at the radiology suite. If the cholangiogram showed normal findings, the T-tube was removed and an intraabdominal drain was placed via the same T-tube track. The tip of the intraabdominal drain was placed adjacent (extraluminal) to the exit site of the T-tube from the native bile duct. The intraabdominal drain was connected to an extracorporeal bag. The purpose of this intraabdominal drain was to remove any bile leak from the previous exit site of the T-tube immediately after T-tube removal. This drain is withdrawn at the bedside for an approximately 1–2 cm every 2 hours until it is completely removed.

For the hepaticojejunostomy, the biliary anastomosis was also accomplished with interrupted stitches using monofilament absorbable sutures. A short internal biliary anastomotic stent was placed and secured with a monofilament absorbable suture. After degradation and absorption of the absorbable anchor suture, the short internal biliary stent spontaneously dislodged and passed through the gastrointestinal tract.

Outcomes Measures

The primary end point was 1-year graft failure-free survival. Graft failure was defined as either the need for retransplantation or death due to primary graft nonfunction or biliary complication. Secondary outcome measures focused on BC after OLT, defined as either biliary anastomotic leak or stricture. In addition, the Clavien-Dindo Classification of Surgical Complication was utilized to grade the severity of BC.12

Statistical Analysis

Patient and graft failure-free survival curves were computed using Kaplan-Meier methods and compared using log rank tests. Medians with interquartile ranges of continuous variables and means were compared using the Wilcoxon tests and proportions using the chi-squared test. Cox proportional hazard was used for univariate and multivariate analyses. A P
value of <0.05 was considered significant in the multivariate analysis. Statistical analysis was performed using SAS software, version 9.1 (SAS Institute).

RESULTS
TransplantRecipientCharacteristics
Among the 149 OLTs performed, 58 (39%) recipients underwent a single-stage OLT procedure (Group I) and 91 (61%) underwent SBRALT (Group II). Table 1 compares the recipient characteristics between the 2 groups. Regarding indication for OLT, hepatic malignancy or chronic hepatitis C infection was more common in Group I (43.1%) compared with Group II (24.2%), \(P = 0.016\). Compared with Group I, patients in Group II have a significantly higher acuity of illness (median laboratory MELD score of 19 vs 34.5, \(P = 0.002\)), required pre-OLT hospitalization (37.9% vs 59.3%, \(P = 0.001\)), intensive care management (29.3% vs 54.9%, \(P = 0.002\)), and pre-OLT renal replacement therapy (15.5% vs 48.4%, \(P < 0.001\)). Moreover, a higher proportion of patients in Group II have pretransplant comorbidities, such as systemic hypertension (17.2% vs 36.3%, \(P = 0.012\)), chronic kidney disease (13.8% vs 37.4%, \(P = 0.002\)), and severe portal hypertension (1.7% vs 12.1%, \(P < 0.001\)).

Deceased Donor Characteristics
Table 2 shows the deceased donor characteristics. All patients received deceased donor hepatic grafts. For both groups, majority of the liver grafts utilized (95%) were from donation after brain death donors. The proportion of liver grafts procured after circulatory death (donation after circulatory death) were also similar for Group I (5.2%) and Group II (4.4%), \(P = 0.823\). While the median donor age in years (interquartile range, IQR) in Group I was significantly older than in Group II, 43 (24–54) versus 32 (23–44), \(P = 0.015\), the amount of blood products required during the OLT phase (Table 3), the median (IQR) days for SBRALT in Group II was 2 days (1–4) versus 1 day (1–3), \(P = 0.016\). Compared with Group I, patients in Group II had significantly better acid-base balance (base excess −2.65 vs −2.55, \(P < 0.001\)) and required less vasopressor agents during this operative phase. While Group II received a significantly higher volume of blood product transfusion during the OLT phase (Table 3), the median (IQR) days for SBRALT in Group II was 2 days (1–4) versus 1 day (1–3), \(P = 0.016\).

TABLE 1: Pretransplantrecipientcharacteristics

| Characteristics                  | Group I (n = 58) | Group II (n = 91) | \(P\)  |
|----------------------------------|-----------------|------------------|-------|
| Age, median, y (IQR)             | 56 (50–61)      | 58 (49–63)       | 0.430 |
| Gender, male, No. (%)            | 34 (58.6)       | 63 (69.2)        | 0.185 |
| Diagnosis, No. (%)               |                 |                  |       |
| Malignancy/hepatitis C infection | 25 (43.1)       | 22 (24.2)        | 0.016 |
| Alcoholic liver disease          | 9 (15.5)        | 30 (32.9)        | 0.018 |
| Nonalcoholic liver disease       | 4 (6.9)         | 4 (4.4)          | 0.511 |
| PSC/PBC                          | 5 (8.6)         | 10 (10.9)        | 0.226 |
| Acute liver failure              | 8 (13.8)        | 5 (5.5)          | 0.081 |
| Diabetes, No. (%)                | 19 (32.8)       | 38 (41.8)        | 0.270 |
| Coronary artery disease, No. (%) | 5 (8.6)         | 14 (15.4)        | 0.227 |
| Systemic hypertension, No. (%)    | 10 (17.2)       | 33 (36.3)        | 0.012 |
| Chronic kidney disease, No. (%)  | 8 (13.8)        | 34 (37.4)        | 0.002 |
| Severe portal hypertension, No. (%)| 1 (1.7)        | 11 (12.1)        | <0.001|
| MELD Score (laboratory), Median (IQR) | 19 (10–34)    | 35 (16–41)       | 0.002 |
| Pre-OLT hospitalization, No. (%) | 22 (37.9)       | 54 (59.3)        | 0.001 |
| Pre-OLT ICU stay, No. (%)        | 17 (29.3)       | 50 (54.9)        | 0.002 |
| Pre-OLT mechanical ventilation, No. (%) | 8 (13.8)       | 24 (26.6)        | 0.065 |
| Pre-OLT hemodialysis, No (%)     | 9 (15.5)        | 44 (48.4)        | <0.001|
| Pre-OLT ≥ 2 vasopressors, No. (%)| 2 (3.4)         | 6 (6.7)          | 0.392 |

ICU, intensive care unit; IQR, interquartile range; MELD, model for end-stage liver disease; OLT, orthotopic liver transplantation; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis.

OperativeVariablesDuringOLTandBiliary ReconstructionPhases
A comparison of the operative variables during OLT and biliary reconstruction are shown in Tables 3 and 4, respectively. The median graft cold ischemia time (330 vs 340 min) and warm ischemia time (42 vs 41 min) in Groups I and II, respectively, were similar. A higher proportion of patients in Group II required intraoperative renal replacement therapy and venovenous bypass.

Table 4 compares the operative variables during biliary reconstruction. Compared with Group I, the patients in Group II had significantly better acid-base balance (base excess −0.1 vs −2.55, \(P < 0.001\)) and required less vasopressor agents during this operative phase. While Group II received a significantly higher volume of blood product transfusion during the OLT phase (Table 3), the median days for SBRALT in Group II was 2 days (1–4) versus 1 day (1–3), \(P = 0.016\).

PosttransplantOutcomes
Compared with Group I, Group II had longer hospitalization after OLT (26.2 vs 45.7 days, \(P < 0.001\), mean ICU
### TABLE 2. Deceased donor characteristics

| Characteristics                  | Group I (n = 58) | Group II (n = 91) | P    |
|----------------------------------|-----------------|------------------|------|
| Age, median, y (IQR)             | 43 (24–54)      | 32 (23–44)       | 0.015|
| Gender, male, No. (%)            | 34 (58.6)       | 47 (51.6)        | 0.500|
| Donor type, DCD (%)              | 3 (5.2)         | 4 (4.4)          | 1.000|
| Cause of death (%)               |                 |                  |      |
| Cerebrovascular accident         | 21 (45.8)       | 24 (32.9)        | 0.091|
| Trauma                           | 10 (23.2)       | 23 (31.5)        | 0.341|
| Anoxia/ asphyxia                 | 8 (18.6)        | 17 (23.4)        | 0.554|

Preprocurement laboratory tests:

- ALT, unit/L: 78.6 vs. 46.3, P = 0.061
- AST, unit/L: 53.5 vs. 35, P = 0.071
- Total bilirubin, mg/dL: 1.5 vs. 0.8, P = 0.252

ALT, alanine aminotransferase; AST, aspartate aminotransferase; DCD, donation after circulatory death; IQR, interquartile range.

### TABLE 3. Comparison of operative variables during OLT by group

| Factors                                      | Group I (n = 58) | Group II (n = 91) | P    |
|----------------------------------------------|-----------------|------------------|------|
| Graft cold ischemia time, min, median (IQR)  | 330 (278–382)   | 340 (295–418)    | 0.234|
| Graft warm ischemia time, min, median (IQR)  | 42 (36–44)      | 41 (37–47)       | 0.952|
| Venovenous bypass, No. (%)                   | 21 (36.2)       | 60 (63.9)        | <0.001|
| Intraoperative CRRT, No. (%)                 | 9 (15.9)        | 44 (48.4)        | <0.001|
| Estimated blood loss, mL, median (IQR)       | 2000 (1000–3250) | 4750 (2250–6500) | <0.001|

Blood transfusion requirement during OLT:

- pRBC, units, median (IQR): 4 (2–9) vs. 10 (5–23), P <0.001
- FFP, units, median (IQR): 6 (2–9) vs. 8 (2–18), P = 0.069
- Cryoprecipitate, units, median (IQR): 0 (0–2) vs. 4 (0–10), P = 0.006
- Operative time, min, median (IQR): 347 (302–420) vs. 372 (290–485), P = 0.329

CRRT, continuous renal replacement therapy; FFP, fresh frozen plasma; IQR, interquartile range; OLT, orthotopic liver transplantation; pRBC, packed red blood cells.

### TABLE 4. Comparison of operative variables during biliary reconstruction by group

| Factors                                      | Group I (n = 58) | Group II (n = 91) | P    |
|----------------------------------------------|-----------------|------------------|------|
| Interval between OLT and BR, median (IQR), days | 0 (0)           | 2 (2–3)          | <0.001|
| Type of biliary reconstruction, No. (%)      |                 |                  |      |
| CC                                           | 53 (91.4)       | 68 (74.7)        | 0.011|
| RYHJ                                         | 5 (8.6)         | 24 (26.4)        | 0.010|
| Blood Base excess, median (IQR)              | −2.55 (−3.82 to 0.45) | −0.1 (−1.77 to 1.27) | <0.001|
| Pts requiring vasopressors at time of BR, No. (%) | 18 (36)       | 25 (28)          | 0.305|
| Pts requiring ≥2 vasopressors, No. (%)       | 11 (21.1)       | 7 (8)            | 0.026|
| Estimated blood loss, median (IQR), mL        | 750 (250–1500)  | 200 (150–475)    | <0.001|

Blood transfusion requirement during BR:

- pRBC, units, median (IQR): 2 (0–4) vs. 0 (0–1), P <0.001
- FFP, units, median (IQR): 2 (0–4) vs. 0 (0–0), P <0.001
- Cryoprecipitate, units, median (IQR): 0 (0–0) vs. 0 (0–0), P = 0.05
- Platelets, units, median (IQR): 0 (0–11) vs. 0 (0–1), <0.001

BR, biliary reconstruction; CC, choledochocholedochostomy; FFP, fresh frozen plasma; IQR, interquartile range; OLT, orthotopic liver transplantation; pRBC, packed red blood cells; RYHJ, roux-en-y hepaticojejunostomy.

### TABLE 5. Indications for hepaticojejunostomy

| Indications                                      | Group I (n = 5) | Group II (n = 24) | P    |
|--------------------------------------------------|-----------------|------------------|------|
| Native bile duct unsuitability (%)               | 1 (20)          | 13 (54.2)        | 0.330|
| Need for bile duct resection at OLT              | 2 (40)          | 5 (20.8)         | 0.569|
| Prior hepaticojejunostomy                       | 2 (40)          | 1 (4.2)          | 0.068|
| Conversion from choledochocholedochostomy        | 0               | 5 (20.8)         | 0.553|

OLT, orthotopic liver transplantation.
length of stay (7.5 vs 18.6 days, \( P < 0.001 \)), mean number of days on the ventilator (3.3 vs 10.9, \( P < 0.001 \)), and CRRT (1.07 vs 3.68, \( P = 0.021 \)).

The overall incidence rate for BC was 8.1%. There was no difference in the incidence rate of BC between Group I (8.6%) and Group II (7.7%), \( P = 0.955 \). Figure 1 shows the 1-year cumulative incidence of BC by group. Table 6 compares the types of BC, times of onset of BC after biliary reconstruction, Clavien-Dindo Classification of Surgical Complications, and management of BC. Surgical intervention for BC was required in only 1 patient in Group I while it was necessary for all patients in Group II. Among these patients in Group II, 5 of 24 (20.8%) patients required conversion from choledochocholedochostomy to hepaticojejunostomy (Table 5). For both groups, there was no graft failure or patient death due to BC.

The vascular complication rate was 3.4% (Group I) and 3.3% (Group II). The incidence of hepatic artery thrombosis was 3.4% in Group I and 1.1% in Group II. Although the acuity of illness was significantly higher in Group II, the 1-year graft failure-free survival rates were comparable for Group I (89.7%) and Group II (88.2%), \( P = 0.845 \) (Figure 2).

For Group II, 17 of 91 patients (18.7%) required additional planned re-laparotomy procedures for staged abdominal closure due to loss of abdominal domain secondary to visceral edema and bowel distention. Incidental unexpected intraoperative findings were noted in 30.8% of the cases: 23 (25.3%) patients were found to have intraabdominal blood clots and required evacuation, 4 (4.4%) with suboptimal hepatic arterial blood flow and underwent hepatic arterial modulation procedures (splenic artery ligation and release of median arcuate ligament), and 1 (1.1%) with segmental ischemic colon requiring partial colectomy.13

**DISCUSSION**

BC after OLT remain causes of significant patient morbidity and mortality, particularly in patients with the highest acuity of illness. While surgical refinements have resulted in improvement of outcomes, nontechnical risk factors also contribute substantially to the development of BC following OLT. These factors include compromised hepatic arterial flow, severe malnutrition, coagulopathy, use of high doses of steroids for immunosuppression, prolonged cold organ preservation duration, and immunological factors.14-17 Furthermore, critically ill patients frequently exhibit hemodynamic instability, severe metabolic derangement, hypothermia, visceral edema, and bowel distention during OLT, rendering them at increased the risk for BC when biliary reconstruction is performed under these conditions.6,18,19

**TABLE 6.**

Comparison of biliary complication type, classification, and management

|Patients| BC type| Time to BC (days)| Clavien-Dindo Classification| Management |
|---|---|---|---|---|
|Group I| 1| Leak| 15| IIIa| ERCP/Stent |
|2| Stricture| 42| IIIa| ERCP/Stent |
|3| Stricture| 289| IIIa| ERCP/Stent |
|4| Leak| 185| IIIa| ERCP/Stent |
|5| Leak| 2| IIIb| Revision of CC with T-tube |
|Group II| 1| Leak| 22| IIIb| Conversion to RYHJ |
|2| Leak| 11| IIIb| Conversion to RYHJ |
|3| Leak| 24| IIIb| Conversion to RYHJ |
|4| Leak| 21| IIIb| Conversion to RYHJ |
|5| Leak| 12| IIIb| Revision of CC with T-tube |
|6| Leak| 17| IIIb| Conversion to RYHJ |
|7| Leak| 29| IIIb| Revision of RYHJ |

BC, biliary complication; CC, choledochocholedochostomy; ERCP, endoscopic retrograde cholangio-pancreatography; RYHJ, roux-en-y hepaticojejunostomy.
The surgical approach to biliary reconstruction following OLT has evolved with regard to optimal timing and anatomic preference. Despite a significant rise in patient acuity, comparable survival rates can be achieved. Surgical strategies which may positively impact both short- and long-term outcomes include a damage control approach following hepatic graft reperfusion. Perihepatic packing and temporary abdominal closure with delayed biliary reconstruction have been employed with reasonable success during massive intraoperative bleeding. Busuttil et al. from the University of California, LA, recently reported their experience with damage control in the setting of OLT. Interestingly, despite hemodynamic instability and ongoing hemorrhage, outcomes were comparable comparing the damage control recipients and those undergoing primary biliary reconstruction.

In the present study, recipients who underwent SBRALT had a significantly higher MELD score, concomitant coronary artery disease, severe portal hypertension, required a pretransplant ICU stay, and intraoperative renal replacement therapy. As such, it is not surprising that the SBRALT group required more blood products during the initial procedure. Cumulatively, these data suggest a benefit to delaying the biliary reconstruction as the need for vasopressors and blood products, as well as the degree of metabolic acidosis, were significantly reduced in the SBRALT cohort during the biliary reconstruction phase. Noteworthy is the relatively low rate of BC (7.7%) in our cohort despite high patient acuity (median MELD score of 35). While all BC in Group II required surgical intervention, 4 out of 7 cases (57%) were incidental subclinical findings during a planned re-laparotomy for staged abdominal closure. These subclinical bile leaks were most likely due to sequelae of critical illness, such as persistent tissue edema, malnutrition, delayed wound healing, and hemodynamic swings during the immediate posttransplantation period. The classification of all BC was grade IIIa or IIIb and none of the graft failure or patient death was due to BC.

While these findings are encouraging, we acknowledge several limitations of this study. In general, the retrospective design and modest number of patients render drawing firm conclusions difficult. Furthermore, we recognize that the care for high-acuity patients with end-stage liver disease and those receiving OLT requires a multidisciplinary critical care management and that SBRALT as well as intraoperative renal replacement therapy during OLT are part of the surgical strategy to optimize outcomes in high-acuity liver transplant recipients. As such, this specialized approach may contribute to, at least in part, the observed outcomes.

Based upon the findings in the present study, the risk of BC in complex OLT could be further reduced by utilizing a staged operative approach, SBRALT. We recommend an assessment of the patient’s suitability to proceed with the traditional one-stage OLT after hepatic graft reperfusion. SBRALT should be considered for patients meeting the following criteria after hepatic graft reperfusion: hemodynamic instability requiring high doses of vasopressive agents, severe coagulopathy requiring massive transfusion of blood products, metabolic acidosis, hypothermia, need for additional lysis of intraabdominal adhesions, and significant visceral edema and bowel distention. Deferring the second operative stage (biliary reconstruction) allows for a brief period of patient resuscitation and stabilization as well as hepatic graft recovery from the inherent ischemia-reperfusion injury. This 2-stage OLT surgical approach provides an optimal milieu for biliary reconstruction, reducing the need for transfusion of blood products and hemodynamic support as well as minimizing the risk of BC in high-acuity transplant recipients.

In conclusion, biliary strictures and leaks are serious complications after OLT that decrease patient and graft survival. Avoidance of these complications is critical to the success of OLT and patient survival. Our study shows excellent outcomes of SBRALT in high-acuity transplant recipients and is an important surgical strategy in complex OLT.

REFERENCES

1. Samstein B, Smith AR, Freise CE, et al. Complications and their resolution in recipients of deceased and living donor liver transplants: findings from the A2ALL cohort study. Am J Transplant. 2016;16:594–602.
2. Zimmerman MA, Baker T, Goodrich NP, et al. Development, management, and resolution of biliary complications after living and deceased donor liver transplantation: a report from the adult-to-adult living donor liver transplantation cohort study consortium. Liver Transpl. 2013;19:259–267.
3. Axelrod DA, Doebishawil N, Lentine KL, et al. Variation in biliary complication rates following liver transplantation: implications for cost and outcome. Am J Transplant. 2015;15:170–179.
4. Muller X, Marcon F, Sapin Gin, et al. Defining benchmarks in liver transplantation: a multicenter outcome analysis determining best achievable results. Ann Surg. 2018;267:419–425.
5. Greif F, Bronnshier CL, Van Thiel DH, et al. The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Am Surg. 1994;219:40–45.
6. DiNocia J, Lee MK, Hiarland-Locke MP, et al. Damage control as a strategy to manage postreperfusion hemodynamic instability and coagulopathy in liver transplant. JAMA Surg. 2015;150:1066–1072.
7. Kim J, Zimmerman MA, Lerret SM, et al. Staged biliary reconstruction after liver transplantation: a novel surgical strategy for high acuity pediatric transplant recipients. Surgery. 2019;165:323–328.
8. Freeman RB, Jr, Wiesner RH, Roberts JP, et al. Improving liver allocation: MELD and PELD. Am J Transplant. 2004;4(4 Suppl 9):114–131.
9. Fanelli F. The evolution of transjugular infrahepatic portosystemic shunt: tips. ISRN Hepatol. 2014;2014:762096.
10. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(2 Suppl 1):S121–S131.
11. Hong JC, Yeriaz H, Farmer DG, et al. Longterm outcomes for whole and segmental liver grafts in adult and pediatric liver transplant recipients: a 10-year comparative analysis of 2,988 cases. J Am Coll Surg. 2009;208:682–9; discussion 689.
12. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;230:205–213.
13. Riez JF, Rosenthal F, Roberts JP, et al. Planned exploration of pediatric liver transplant recipients reduces posttransplant morbidity and lowers length of hospitalization. Arch Surg. 1997;132:950–5; discussion 955.
14. Seehofer D, Eichri D, Veltzke-Schlieker W, et al. Biliary complications after liver transplantation: old problems and new challenges. Liver Transpl. 2013;13:253–265.
15. Duffy JP, Hong JC, Farmer DG, et al. Vascular complications of orthotopic liver transplantation: experience in more than 4,200 patients. J Am Coll Surg. 2009:208:896–903; discussion 903.
16. Verdonk RC, Buis CJ, Porte RJ, et al. Anastomotic biliary strictures in living and deceased donor liver transplantation: causes and consequences. Liver Transpl. 2006;12:726–735.
17. Kakizoe S, Yanaka G, Starzy TE, et al. Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: considerations of preservation and early immunological injury. Hepatology. 1990;11:932–941.
18. Zimmerman MA, Selim M, Kim J, et al. Outcome analysis of continuous intraoperative renal replacement therapy in the highest acuity liver transplant recipients: a single-center experience. Surgery. 2017;161:1279–1286.
19. Rana A, Petrowsky H, Hong JC, et al. Blood transfusion requirement during liver transplantation is an important risk factor for mortality. *J Am Coll Surg.* 2013;216:902–907.

20. Agopian VG, Petrowsky H, Kaldas FM, et al. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. *Ann Surg.* 2013;258:409–421.

21. Petrowsky H, Rana A, Kaldas FM, et al. Liver transplantation in highest acuity recipients: identifying factors to avoid futility. *Ann Surg.* 2014;259:1186–1194.

22. Alexopoulos S, Matsuoka L, Cho Y, et al. Outcomes after liver transplantation in patients achieving a model for end-stage liver disease score of 40 or higher. *Transplantation.* 2013;95:507–512.

23. Komorowski AL, Li WF, Millan CA, et al. Temporary abdominal closure and delayed biliary reconstruction due to massive bleeding in patients undergoing liver transplantation: an old trick in a new indication. *J Hepatobiliary Pancreat Sci.* 2016;23:118–124.

24. Zimmerman MA, Selim M, Kim J, et al. A specialized transplantation critical care model: expanding liver transplantation access to high-acuity patients. *Transplant Proc.* 2018;50:2619–2621.